Out of 9 analysts covering Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), 9 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $126 is the highest target while $67 is the lowest. The $99.11 average target is 41.46% above today’s ($70.06) stock price. Ultragenyx Pharmaceutical Inc has been the topic of 13 analyst reports since October 23, 2015 according to StockzIntelligence Inc. Wedbush maintained the stock on May 10 with “Outperform” rating. Below is a list of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) latest ratings and price target changes.
10/05/2016 Broker: Wedbush Rating: Outperform Old Target: $99.00 New Target: $92.00 Maintain
28/06/2016 Broker: Bank of America Rating: Buy Initiate
08/06/2016 Broker: JMP Securities Rating: Market Outperform Old Target: $80.00 New Target: $84.00 Maintain
About 411,057 shares traded hands. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) has risen 40.75% since February 8, 2016 and is uptrending. It has outperformed by 24.26% the S&P500.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $2.97 billion. The Firm is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. It currently has negative earnings. The Firm is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.
The institutional sentiment decreased to 0.97 in 2016 Q2. Its down 0.12, from 1.09 in 2016Q1. The ratio worsened, as 19 funds sold all Ultragenyx Pharmaceutical Inc shares owned while 55 reduced positions. 19 funds bought stakes while 53 increased positions. They now own 36.54 million shares or 1.13% less from 36.95 million shares in 2016Q1.
Iguana Healthcare Management Llc holds 2.79% of its portfolio in Ultragenyx Pharmaceutical Inc for 140,000 shares. Weatherbie Capital Llc owns 337,788 shares or 2.34% of their US portfolio. Moreover, Opaleye Management Inc. has 2.12% invested in the company for 65,000 shares. The Israel-based Sphera Funds Management Ltd. has invested 1.33% in the stock. Cormorant Asset Management Llc, a Massachusetts-based fund reported 110,842 shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.